US Patent

US10729739 — Methods of treating prostate cancer with GnRH antagonist

Method of Use · Assigned to Ferring BV · Expires 2029-02-10 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating androgen-dependent prostate cancer using a gonadotrophin releasing hormone (GnRH) antagonist.

USPTO Abstract

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

Drugs covered by this patent

degarelix-acetate (DEGARELIX ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1978`	—	degarelix-acetate
`U-1978`	—	degarelix-acetate

Patent Metadata

Patent number: US10729739
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-10
Drug substance claim: No
Drug product claim: No
Assignee: Ferring BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.